– USA, MA – Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Dr. Claire Fraser (Ph.D.) to its Board of Directors, effective immediately.
“Dr. Fraser brings deep expertise driving forward the science of the microbiome and we expect her to be an invaluable addition to our Board supporting the development of future microbiome medicines and the continued success of Seres,” said Board Chairman, Steve Berenson.
CEO, Eric Shaff. added, “I look forward to collaborating with Dr. Fraser, whose work has provided important contributions that have supported the emergence of the microbiome industry for years. We continue to advance our pipeline, delving deeper into our Infection Protection strategy to address unmet needs in medically compromised individuals, including those with cancer neutropenia, cirrhosis, and solid organ transplant. Dr. Fraser’s experience will serve as the perfect complement to the knowledge and development expertise we have built at Seres over the last decade.”
About Dr. Claire M. Fraser
Dr. Fraser is the Director of The Institute for Genome Sciences, which she launched in 2007, at the University of Maryland School of Medicine. She also serves as a faculty member in the Departments of Medicine and Microbiology/Immunology. Before this, she held positions as President and Director of The Institute for Genomic Research; Chief of the Section on Molecular Neurobiology in the Laboratory of Physiologic and Pharmacologic Studies at the National Institute on Alcohol Abuse and Alcoholism; Senior Staff Fellow and Chief of the Unit of Receptor Regulation, Receptor Biochemistry and Molecular Biology at the Laboratory of Molecular and Cellular Neurobiology within the National Institutes of Health; and a Cancer Research Scientist at Roswell Park Memorial Institute.
“It is an incredibly exciting time to be joining the Seres Board of Directors as the company prepares for its first potential product approval with SER-109 in recurrent C. difficile infection,” said Dr. Claire Fraser. “In my view, the success of SER-109 bodes well for Seres’ broader pipeline of new clinical candidates using microbiome therapeutics as a novel approach for Infection Protection for medically compromised individuals and antimicrobial resistance more generally. I look forward to being a part of a company working diligently to continue to bring the promise of such microbiome therapeutics to patients.”
She graduated from Rensselaer Polytechnic Institute in Troy, NY, and received her Ph.D. in pharmacology from the State University of New York at Buffalo. She was elected as a member of the National Academy of Medicine in 2011 and recently concluded a term as President of the American Association for the Advancement of Science (AAAS).
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has the potential to become a first-in-class FDA-approved oral microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also researching to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, visit www.serestherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.